RxDoctor Payments Data

James Starr, DO

Neurology · Gainesville, GANPI 1942567060

Payments from drug & device makers

$8,865in general payments, 2019–2025

Across 410 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$899
  • UCB, Inc.$777
  • Pfizer$578
  • Teva Pharmaceuticals USA, Inc.$478
  • MDD US Operations, LLC$472
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$7809%
  • Speaking & faculty fees$340%
  • Food & beverage$8,05191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,865 in reported general payments places this provider in the 70th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$232,057
Medicare patients
361
Services billed
20,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine42$342,490
NuplazidPimavanserin Tartrate44$269,356
IngrezzaValbenazine Tosylate22$215,524
AubagioTeriflunomide12$198,966
Austedo XrDeutetrabenazine14$182,431
Nurtec OdtRimegepant Sulfate67$107,342
GocovriAmantadine Hcl17$89,391
RytaryCarbidopa/Levodopa51$80,510
BotoxOnabotulinumtoxina58$69,666
UbrelvyUbrogepant44$64,137
NourianzIstradefylline16$41,759
BriviactBrivaracetam20$29,704
Rasagiline Mesylate178$23,931
Carbidopa-LevodopaCarbidopa/Levodopa430$10,946
Emgality PenGalcanezumab-Gnlm13$9,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$478$524,92056 claims
Acadia Pharmaceuticals IncNuplazid$200$269,35644 claims
Neurocrine Biosciences, Inc.Ingrezza$276$215,52422 claims
AbbVieBotox, Ubrelvy$1,840$133,803102 claims
PfizerNurtec Odt$578$107,34267 claims
MDD US Operations, LLCGocovri$472$89,39117 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$255$82,64368 claims
Kyowa Kirin, Inc.Nourianz$169$41,75916 claims
UCB, Inc.Briviact$777$29,70420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 506 neurology providers in Georgia.

Other neurology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →